Skip to main content
    1. Home

    • UCB Medicines: Clinical Studies and Scientific Research Publication

    Publications

    This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.

    Select product(s):
    Select topic(s):
    Phase:

    *Includes seizure clusters and acute or prolonged seizures

    189 result(s)

    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
    View

    Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2 

    Navarro-Compán Victoria, Ramiro Sofia, Deodhar Atul et al.  April 10, 2024
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Plaque Psoriasis
    View

    Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials

    Lebwohl Mark, Joseph F Merola, Strober Bruce et al.  April 06, 2024
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Plaque Psoriasis
    View

    Bimekizumab-bkzx Journal Scan: 4 Clinical Trials

    Jason Hawkes et al.  March 25, 2024
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Plaque Psoriasis
    View

    Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials

    Gordon B. Kenneth, Langley G. Richard, Warren B. Richard et al.  March 15, 2024
    phase 2

    BIMZELX® (bimekizumab-bkzx)

    Plaque Psoriasis
    View

    Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials

    Blauvelt Andrew, Armstrong April, Joseph F Merola et al.  March 04, 2024
    phase 4/RWE

    BRIVIACT® (brivaracetam) CV

    Focal Onset Seizures
    View

    Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis

    Jerzy P Szaflarski, Hervé Besson, Wendyl D'Souza et al.  March 04, 2024
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Plaque Psoriasis
    View

    Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials

    Blauvelt Andrew, Armstrong April, Joseph F Merola et al.  March 04, 2024
    phase 3

    ZILBRYSQ® (zilucoplan)

    Generalized Myasthenia Gravis
    View

    Improvement of fatigue in generalised myasthenia gravis with zilucoplan

    Weiss D. Michael, Freimer Miriam, M. Isabel Leite et al.  February 24, 2024
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Psoriatic Arthritis
    View

    Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

    Coates C. Laura, Landewé B.M. Robert, Iain B McInnes et al.  February 22, 2024
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Psoriatic Arthritis
    View

    Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis in Arthritis Research and Therapy 

    Laure Gossec, Brittany Humphries, Megan Rutherford et al.  February 15, 2024